AstraZeneca UK Limited
AstraZeneca UK Limited, a prominent player in the global pharmaceutical industry, is headquartered in Great Britain. Founded in 1999 through the merger of Astra AB and Zeneca Group PLC, the company has established itself as a leader in the development of innovative medicines across various therapeutic areas, including oncology, cardiovascular, and respiratory health. With a strong presence in Europe, North America, and Asia, AstraZeneca is renowned for its commitment to research and development, investing significantly in cutting-edge science. The company’s core products, such as the COVID-19 vaccine and treatments for cancer, are distinguished by their efficacy and safety profiles, contributing to AstraZeneca's reputation for excellence. Recognised for its robust pipeline and strategic partnerships, AstraZeneca continues to achieve notable milestones, solidifying its position as a key player in the pharmaceutical landscape.
DitchCarbon Score
How does AstraZeneca UK Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Real Estate Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
AstraZeneca UK Limited's score of 94 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
AstraZeneca UK Limited, headquartered in Great Britain, currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of AstraZeneca PLC, which cascades its climate commitments and emissions data down to its subsidiaries. AstraZeneca PLC has set ambitious climate targets, including commitments to reduce greenhouse gas emissions across its operations. These targets are aligned with the Science Based Targets initiative (SBTi) and are part of a broader strategy to achieve net-zero emissions by 2025 for its global operations (Scope 1 and 2) and by 2030 for its value chain (Scope 3). The company is also involved in various sustainability initiatives, including the RE100 commitment to 100% renewable electricity and participation in the Carbon Disclosure Project (CDP). These initiatives reflect AstraZeneca's dedication to addressing climate change and reducing its environmental impact. While specific emissions data for AstraZeneca UK Limited is not available, the company's overarching climate commitments and targets inherited from AstraZeneca PLC demonstrate a strong commitment to sustainability and carbon reduction.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 298,498,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 322,319,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
AstraZeneca UK Limited is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
